海南海药(000566.SZ)子公司获富马酸伏诺拉生片药品注册批件

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for a new chemical drug, indicating a positive development in its product pipeline and potential market expansion [1] Group 1 - The company announced that its wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the Drug Registration Certificate for "Fumaric Acid Vonoprazan Tablets" from the National Medical Products Administration [1] - The registered indication for the drug is gastroesophageal reflux disease, which is a significant condition that affects many patients [1] - The drug is intended to be used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori, a common bacterial infection linked to various gastrointestinal diseases [1]